Statement: A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.
Primary_evidence: Adverse Events 1:   Total: 20/93 (21.51%)   Granulocytosis 1/93 (1.08%)   Leukopenia 2/93 (2.15%)   Angina pectoris 0/93 (0.00%)   Atrial fibrillation 1/93 (1.08%)   Cardiopulmonary failure 2/93 (2.15%)   Retinal detachment 1/93 (1.08%)   Diarrhoea 3/93 (3.23%)   Nausea 1/93 (1.08%)   Vomiting 1/93 (1.08%)   Chest pain 1/93 (1.08%)   Death 0/93 (0.00%)   Pyrexia 1/93 (1.08%)